Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites
Pancreatology · 2024
DOI: 10.1016/j.pan.2024.07.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2024. Verfasst von Chiharu Uchiyama und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Ascites, Palliative Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: The management of malignant ascites is critical for treating patients with advanced pancreatic cancer. The purpose of this study was to assess the safety of cell-free and concentrated ascites reinfusion therapy (CART) and its impact on the prognosis of patients with advanced pancreatic cancer who have massive malignant ascites. METHODS: This study analyzed 47 procedures in 29 patients who underwent CART for ascites caused by pancreatic cancer between 2015 and 2022. Among them, 7 patients who received chemotherapy following CART were classified as the chemotherapy group, while 22 patients without chemotherapy after CART were classified as the palliative care group. RESULTS: Among the 47 procedures, adverse events (AEs) were observed in 9 procedures (19 %). Grade 2 adverse events were observed only in one procedure, manifested as fever. There were no grade 3 or 4 AEs, nor were there any treatment-related deaths. The median survival time was 4.0 months in the chemotherapy group and 0.7 months in the palliative care group (p = 0.004). The albumin level in the chemotherapy group was significantly higher than that in the palliative care group. CONCLUSION: CART is feasible and might be the optimal option to enable prolonged use of chemotherapy to improve the prognosis for late-stage pancreatic cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
- Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. Electronic address: m-sho@naramed-u.ac.jp.
Zitieren
APA
Uchiyama, C., Terai, T., Nagai, M., Nakamura, K., Kohara, Y., Yasuda, S., Matsuo, Y., Doi, S., Sakata, T., & Sho, M. (2024). Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites. Pancreatology. https://doi.org/10.1016/j.pan.2024.07.013
Vancouver
Uchiyama C, Terai T, Nagai M, Nakamura K, Kohara Y, Yasuda S, et al. Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites. Pancreatology. 2024. doi:10.1016/j.pan.2024.07.013
BibTeX
@article{Uchiyama2024,
author = {Uchiyama, Chiharu and Terai, Taichi and Nagai, Minako and Nakamura, Kota and Kohara, Yuichiro and Yasuda, Satoshi and Matsuo, Yasuko and Doi, Shunsuke and Sakata, Takeshi and Sho, Masayuki},
title = {Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites},
journal = {Pancreatology},
year = {2024},
doi = {10.1016/j.pan.2024.07.013}
}
EUVIMED